“Tirzepatide” sounds like a prescription, a science quiz and a tongue twister all at once. The answer is much smaller than the name.
Yes—tirzepatide is a peptide.
The 20-second answer: tirzepatide is a synthetic chain of 39 amino acids. It can activate two receptor systems—GIP and GLP-1—which is why it is called a dual agonist.
Is tirzepatide a peptide?
Yes. A peptide is simply a short chain of amino acids.
Imagine amino acids as beads. String a small number of beads together and you have a peptide. Make the chain much longer and more complicated and it may be called a protein.
Tirzepatide has 39 amino-acid “beads.” Scientists started with the shape of a natural GIP signal and made careful changes so the finished peptide could do more and stay around longer. A published review describes it as a 39-amino-acid synthetic peptide, and the FDA confirms that tirzepatide is based on the GIP sequence in its official Zepbound label.
What does “dual GIP/GLP-1 agonist” mean?
This phrase looks like alphabet soup. It is actually the most interesting part.
GIP and GLP-1 are natural signals involved in what the body does after eating. Each has its own receptor on cells.
Tirzepatide is unusual because one molecule can activate both the GIP receptor and the GLP-1 receptor. That is why people call it a dual agonist, or sometimes a “twincretin.” The FDA describes the same two-receptor action in its current prescribing information.
One signal, two signals or three?
Here is the whole comparison without the chemistry lecture.
Semaglutide: one
GLP-1
One peptide focused on one receptor system.
Tirzepatide: two
GIP + GLP-1
One peptide designed to activate both receptor systems.
Retatrutide: three
GIP + GLP-1 + glucagon
A triple-agonist peptide built around three receptor systems.
Why can tirzepatide stay around longer?
Natural gut signals do their job and disappear fairly quickly. Researchers gave tirzepatide a clever travel companion: a fatty-acid side chain that helps it bind to albumin, a common protein in the blood.
Think of albumin as a slow-moving shuttle. By catching a ride, the peptide is protected from leaving the scene too quickly. The FDA says this albumin binding helps prolong tirzepatide’s half-life.
That small design feature is a big part of what makes tirzepatide scientifically interesting: it is still a peptide, but it has been engineered to behave very differently from a short-lived natural signal.
Tirzepatide vs semaglutide: why the extra signal matters
Semaglutide is a GLP-1 receptor agonist. Tirzepatide works with GLP-1 and GIP. That extra signal is not just a catchy label; the two peptides have been compared directly in large human studies.
In the 2025 SURMOUNT-5 trial, 751 adults with obesity were assigned to tirzepatide or semaglutide. The tirzepatide group had a greater average reduction in body weight and waist circumference at 72 weeks. You can read the study in The New England Journal of Medicine.
For the numbers, product options, and buyer checklist in one place, see our semaglutide vs tirzepatide comparison.
The simple takeaway is not that every peptide is interchangeable. It is that the number and combination of receptor signals can change what a peptide does.
Tirzepatide vs retatrutide: two receptor targets or three?
Retatrutide takes the same easy idea one step further. It is designed to activate GIP and GLP-1 receptors plus the glucagon receptor.
For the newest human-study numbers, read our plain-English breakdown of the Retatrutide Phase 3 results.
The quick comparison is:
- Semaglutide: one signal
- Tirzepatide: two signals
- Retatrutide: three signals
That makes tirzepatide the middle member of this popular research trio—not in quality or importance, but in the number of receptor systems it activates.
Is tirzepatide the same as Mounjaro or Zepbound?
The molecule is the same, but the words describe different things.
Tirzepatide is the name of the active peptide. Mounjaro and Zepbound are brand names for FDA-approved finished medicines that contain tirzepatide.
Certiva supplies lyophilized tirzepatide as a research reference material. It is not a branded Mounjaro or Zepbound product. That distinction matters when comparing a research vial with a finished prescription medicine.
Looking for tirzepatide research material?
Certiva offers high-purity lyophilized tirzepatide in specifications from 5 mg to 120 mg per vial, with third-party HPLC testing and a Certificate of Analysis available for every batch. Bulk quantities and custom requirements are available by inquiry.
View tirzepatide specifications · See Certiva’s COA process · Ask for the current batch COA and quote
Sources for curious readers
- FDA: current Zepbound prescribing information
- Tirzepatide structure and 39-amino-acid design
- SURMOUNT-5: tirzepatide compared with semaglutide
- Retatrutide triple-agonist phase 2 trial
Frequently asked questions
Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic peptide made from a chain of 39 amino acids. It is designed to activate both GIP and GLP-1 receptors.
Is tirzepatide a GLP-1?
Tirzepatide is more accurately called a dual GIP and GLP-1 receptor agonist. It activates the GLP-1 receptor and also the GIP receptor.
How is tirzepatide different from semaglutide?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors, which is why it is called a dual agonist.
How is tirzepatide different from retatrutide?
Tirzepatide activates two receptor systems, GIP and GLP-1. Retatrutide is designed to activate three, adding the glucagon receptor to GIP and GLP-1.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active peptide in the FDA-approved medicines Mounjaro and Zepbound. The brand names describe finished prescription products, while tirzepatide is the name of the active molecule.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.